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ABSTRACT 
 
Merkel cell carcinoma (MCC) is a rare aggressive skin cancer categorized into 
two subgroups according to presence of Merkel cell polyomavirus (MCV). 
Around 20% of the tumors are polyomavirus negative and associate with 
worse prognosis than MCV-positive tumors. Current treatment modalities 
for advanced MCC are scarce, and new targeted therapies are warranted. 
Therefore, we need to further examine the molecular pathology of MCC with 
respect to the polyomavirus status of the tumor to seek potential 
therapeutic targets. We hypothesized that there could be significant 
differences in microRNA, gene mutation and RNA expression patterns of 
MCV-positive and MCV-negative tumors. In this study, we utilized formalin-
fixed paraffin-embedded primary MCC samples to investigate molecular 
aberrations of MCV-negative and MCV-positive MCC. Microarrays and 
quantitative reverse transcription PCR were used to determine microRNA 
expression, while next-generation sequencing was applied for analyzing 
mutational and RNA expression patterns of MCC tumors. Tumor protein 
expression was examined by immunohistochemistry. Further, clinical details 
of MCC patients were statistically correlated to molecular alterations.  
 
Regarding microRNA patterns, we uncovered different expressions of four 
miRNAs in MCV-negative tumors compared to MCV-positive tumors. The 
most notable of these miRNAs was miRNA-34a, a known tumor suppressor, 
which was underexpressed in MCV-negative tumors and therefore might 
contribute to the pathogenesis of that MCC subgroup. In our sequencing 
projects, we observed generally higher mutational frequency in MCV-
negative tumors.  
  6 
Notably, we recorded unprecedented EGFR mutations in 22% of the MCC 
tumors studied. In addition, there was overexpression of ALK and EZH2 at 
RNA level in MCC tumors. We then proceeded to investigate the expression 
of ALK, EGFR and EZH2 at protein level by immunohistochemistry and found 
frequent expression of ALK and EZH2. Interestingly, ALK expression by 
immunohistochemistry correlated strongly with MCV positivity of the tumor. 
EGFR expression was detected in 7/31 MCV-negative tumors, while none of 
the MCV-positive tumors expressed EGFR. There was no significant 
correlation between the alterations and clinical parameters of the patients. 
We concluded that the relationship of ALK and MCV needs further 
investigation, while EZH2 could be a potential therapeutic target in MCC 
since it is frequently expressed, regardless of the MCV status of the tumor. 
In addition, the subgroup of EGFR positive MCC-negative tumors might 
benefit from EGFR inhibitor treatment. Our results provide evidence that 
there are distinct molecular aberrations in MCV-negative and MCV-positive 
MCC.  
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1 INTRODUCTION 
 
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer of 
neuroendocrine origin. It most often presents in the head and neck region 
of aged individuals; however it can also manifest at younger age, particularly 
alongside an immunocompromising condition (Agelli 2010, Sahi 2010). UV 
radiation is the main extrinsic risk factor for MCC, and thus the incidence 
varies according to geographic location, being highest in locations with 
sustained sun-exposure (Agelli 2010, Youlden 2014). 
 
In 2008, a previously unknown polyomavirus, named Merkel cell 
polyomavirus (MCV), was discovered from  MCC tumor tissue (Feng 2008), 
and since then, MCC has been categorized into MCV-positive and MCV-
negative subgroups. Around 80% of the MCC tumors are MCV-positive, and 
the so-called T antigens encoded by MCV seem to mediate the oncogenic 
properties of the virus (Houben 2010, Shuda 2008, Shuda 2015, Verhaegen 
2015). Even though MCV-negative tumors represent a minority of MCC cases 
(20%), they tend to be more aggressive than MCV-positive tumors (Moshiri 
2017). Notably, the pathogenesis of MCV-negative MCC is weakly 
established. Previous mutational studies have reported various infrequent 
mutations predominantly in MCV-negative tumors, but no key driver 
mutations have been found (Erstad 2014). Besides the mutational profiles, 
there is a lack of knowledge regarding the expression of cancer genes at RNA 
level in MCC. Certain molecules that could alter the expression of oncogenes 
or tumor suppressors are MicroRNAs. Previously, only one study addressed 
the MicroRNA profiles of MCC tumors (Xie 2014), and therefore further 
investigation is warranted. 
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Management of MCC is based on surgical excision of the primary tumor 
which can be a curative treatment. However, for advanced MCC the 
treatment options are scarce (Lebbe 2015). Traditional chemotherapeutics 
are often ineffective, and even though new immunotherapies seem 
effective, some MCC tumors do not respond to them (Kaufman 2016, 
Nghiem 2017). Therefore, there is a demand for new targeted treatments 
taking into account the MCV status and other individual molecular 
characteristics of the tumor. For these treatments to emerge, we need to 
further investigate the genetic and molecular profiles of MCC tumors with 
respect to the tumor MCV status, ultimately to seek for potential therapeutic 
targets.  
 
         
2 REVIEW OF THE LITERATURE 
 
2.1 Skin cancer 
 
Skin cancer is the most frequent type of cancer in humans. There are over 5 
million cases per year accounting for as much as 40% of all cancer cases 
worldwide (GBD 2015 Disease and Injury Incidence and Prevalence 
Collaborators 2016). In Finland, there were 3824 cases of skin cancer in 2016 
according to the Finnish Cancer Registry. The age-standardized mortality was 
4.7/100 000 which constitutes for 265 deaths caused by skin cancer during 
the year 2016 in Finland (Finnish Cancer 
Registry, https://tilastot.syoparekisteri.fi/syovat) The three main skin cancer 
types are melanoma, basal cell carcinoma and squamous cell skin carcinoma. 
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Basal cell carcinoma is the most common of all skin cancers, and together 
with squamous cell carcinoma they belong to the group of non-melanoma 
skin cancers that also includes rare cancer types such as Merkel cell 
carcinoma (Dubas 2013). Figure 1 shows the basic division of skin cancer 
subgroups, and Figure 2 presents the proportions of different skin cancer 
types diagnosed in Finland. In addition to the cancers presented in Figure 1, 
many other cancers can locate on the skin, although not considered as skin 
cancer, and some of these are mentioned in the Table 1.  
 
Ultraviolet (UV) radiation is the primary cause of skin cancer, augmenting 
the risk of all main skin cancer types. It is estimated that over 90% of skin 
cancers result from UV radiation, and exposure to sunlight is the main source 
of UV radiation. Sunbathing and artificial tanning beds are serious worldwide 
health risks (Gallagher 2010). Other risk factors include age, Caucasian skin, 
smoking, ionizing radiation, immunosuppression and viral infections (Apalla 
2017, Saladi 2005, Cakir 2012). The appearances of skin cancers are diverse, 
ranging from discolorations, or ulcers on the skin, to enlargement or other 
changes in an existing mole.  
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Figure 1. The basic classification of skin cancer subgroups. 
 
 
 
2.1.1 Non-melanoma skin cancer 
 
Non-melanoma skin cancers are comprised of a vast number of different 
tumor types, and only the most frequent types are addressed in this 
dissertation. Basal cell carcinoma (BCC) is the most frequently diagnosed 
malignancy, particularly in the Caucasian population (Lomas 2012). 
Incidence of BCC varies between countries, as it is strongly affiliated with the 
geographic location of the country (Verkouteren 2017). The incidence has 
risen around 5 % annually in Europe and 2 % annually in the USA.  The 
average incidence in the UK is 76/100 000 (Lomas 2012, de Vries 2012). In 
Finland, the age-standardized incidence is 162/100 000 for men and 147/100 
000 for women (Finnish Cancer Registry, 2016). The prognosis of BCC is 
typically excellent. It has remarkably low metastasizing rates and generally 
does not affect the survival of patients (Lo 1991).  
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However, it is associated with increased risk of other skin cancers; squamous 
cell carcinoma by 3-fold and melanoma by 2-fold (Flohil 2013). An even more 
evident concern is that primary BCC patients have a 17-fold risk of 
developing another BCC compared to the general population (Flohil 2013). 
 
DNA damage caused by UV radiation is the most renowned cause of BCC. 
BCC often presents as a shiny red nodule with visible small dilated vessels 
called teleangiectasia. It can be ulcerated and thus resemble a chronic 
wound for example. There are three main forms of BCC according to the 
histologically determined growth pattern of the tumor: superficial, 
infiltrative and nodular BCC. The nodular form tends to arise in the head and 
neck region, whereas the superficial form commonly lies on the trunk 
(Verkouteren 2017). BCC is divided into low-risk and high-risk tumors based 
on the location of the tumor and histological growth pattern. Superficial and 
nodular BCC belong to the low-risk group, while the infiltrative type is 
considered as a high-risk tumor. In addition, all the recurrent BCCs as well as 
BCCs occurring on immunosuppressed individuals or on a prior radiation site 
are considered as high-risk tumors (Work Group 2018). Surgical removal of 
the tumor with 3-5 mm margins is normally sufficient treatment for BCC and 
is the recommended treatment for all high-risk tumors. Sometimes for low-
risk BCC, cryotherapy or topical agents such as 5-Fluorouracil or Imiquimod 
are utilized as the primary treatment (Work Group 2018). 
 
The second most frequent non-melanoma skin cancer is squamous cell 
carcinoma (SCC). Similarly to BCC, the incidence of SCC is bound to the 
latitudinal location of the country, as UV radiation is the main risk factor. In 
the UK, the average incidence rate is around 23/100 000 (Lomas 2012). In 
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Finland, the age-standardized incidence in 2016 was 40.2/100 000 for men 
and 23.4/ 100 000 for women. In total, there were 1719 confirmed cases of 
SCC in 2016 (Finnish Cancer Registry). Prognosis of local SCC is fairly good 
since the 5-year survival rate is around 90%. However, SCC is prone to 
metastasize, and the 5-year survival rate lowers to 42% in advanced disease 
(Que 2018). In addition to UV radiation, risk factors for SCC include age, male 
sex, immunosuppression and the human papilloma virus (HPV) infection 
(Didona 2018). The average age of SCC onset  is around 65-years, and it is 
three times more common in men than women. Solid organ transplantation 
and associated immunosuppressive treatment can increase the risk of SCC 
as much as 250 times compared to the general population (Que 2018).  
 
The clinical appearance of SCC is highly variable. It often arises from a pre-
malignant lesion called actinic keratosis or solar keratosis (Fernandez-
Figueras 2015). Actinic keratoses are scaly white or reddish macules typically 
located on sun-exposed skin. Once SCC appears it can form an ulcer or 
necrosis on its center. Sometimes it grows on an existing wound or scar 
tissue. SCC that only grows in the epidermis and not in the deeper layers of 
the skin, in situ carcinoma, is also known as Morbus Bowen (Apalla 2017, 
Ratushny 2012). Like BCC, the treatment of choice for SCC is surgical removal 
of the tumor, either by traditional excision or applying Mohs micrographic 
surgery. Radiation treatment and chemotherapeutics can be utilized for 
advanced SCC (Apalla 2017). 
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About 1% of non-melanoma skin cancers rise from the appendages or 
adnexa of the skin, including sebaceous glands, sweat glands and sensory 
organs. Examples of such entities are sebaceous carcinoma, eccrine 
porocarcinoma and Merkel cell carcinoma (Dubas 2013). 
 
 
2.1.2 Melanoma 
 
Cutaneous melanoma evolves from melanocytes that are cells located in the 
basal layer of the epidermis. As in non-melanoma skin cancers, the incidence 
of melanoma is bound to geographics and ethnicity (Apalla 2017, Erdei 
2010). Melanoma is the second most common form of skin cancer. In 
Finland, there were 1947 confirmed cases in 2016. The age-standardized 
incidence being 38.4/100 000 for men and 33.8/100 000 for women (2016) 
The respective mortality rates are 6.1/100 000 and 2.1/100 000 (Finnish 
Cancer Registry). Melanoma is seemingly more aggressive and lethal 
compared to non-melanoma skin cancers. According to data from the 
Finnish Cancer Registry, from the 265 skin cancer deaths in Finland in 2016, 
80% were caused by melanoma and only 20% by non-melanoma skin 
cancers.   
 
UV radiation exposure is the fundamental risk factor for melanoma. 
Particularly intense, occasional exposure to fair skinned individuals at a 
young age is harmful and increases the risk for melanoma dramatically (Psaty 
2010, Garibyan 2010). In addition to UV radiation, fair skin, positive family 
history and immunosuppression associated with HIV infection or organ 
transplant are risk augmenting factors. Beyond that, previous non-
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melanoma skin cancer multiplies the risk for melanoma by 4-fold (Psaty 
2010, Leachman 2009). Even though quite few melanomas develop on an 
existing mole, the presence of numerous moles clearly increases the risk for 
melanoma (Holly 1987, Tucker 1997). 
 
The classical warning signs or characteristics of melanoma can be 
remembered with ABCDE mnemonic which stands for: Asymmetry, Border 
irregularity, Color variation, Diameter more than 6 mm, Enlarging or Evolving 
(Friedman 1985, Friedman 1991). Standard histological evaluation of 
melanoma includes the definition of Breslow thickness, that is the tumor’s 
maximal thickness in millimeters, and the Clark level, which depicts the 
tumor’s invasion depth according to different skin structures. Clark levels 
range from Level 1, or in situ melanoma, to level 5, or melanoma infiltrating 
the subcutaneous fat (Kauffmann 2014). However, the Clark level currently 
has no significance in clinical practice, whereas the Breslow thickness is 
essential for staging melanoma.  The most important prognostic factors in 
addition to the Breslow thickness are the presence of ulceration and the 
number of mitotic cells in the tumor, all of which predict poorer prognosis 
(Gershenwald 2017). 
 
Wide surgical excision is the main treatment for local invasive melanoma and 
is often curative. Breslow thickness is considered when determining 
sufficient healthy tissue margins. For tumors with thickness over 4 mm, a 
margin of at least 2 cm is recommended (Ethun 2016). Melanoma spreads to 
the lymph nodes vividly, and the employment of Sentinel Lymph Node 
Biopsy (SLNB) is decided based on the Breslow thickness, and SLNB is 
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recommended for at least all melanomas between 1-4 mm in thickness 
(Wong 2018).  
In addition to surgery, treatment options for advanced melanoma include 
systemic targeted therapies with BRAF, CTLA4 and PD-1 inhibitors (Coit 
2016). 
 
 
 
Figure 2. The relative proportions of skin cancer diagnoses in Finland according to 
Finnish Cancer Registry data in 2016.  
 
 
 
 
 
 
Melanoma
16%
SCC
14%
BCC
69%
Others
1%
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Table 1. Many other forms of cancer besides melanoma and non-melanoma skin 
cancers can appear on the skin. Some of those are presented in this table. 
 
Other cancers that can locate on the skin 
Dermatofibrosarcoma Protuberans 
Kaposi’s Sarcoma 
Paget’s Disease 
Leiomyosarcoma 
Angiosarcoma 
Cutaneous T-cell lymphoma 
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2.2 Merkel cell carcinoma 
 
Merkel cell carcinoma (MCC) was first introduced in 1972 as trabecular 
carcinoma of the skin (Toker 1972). Since then, many names have been 
coupled to this malignancy such as primary small-cell carcinoma of the skin, 
neuroendocrine carcinoma of the skin and Merkel cell carcinoma (Hitchcock 
1988). MCC was historically thought to arise from Merkel cells, 
mechanoreceptors located on the basal layer of epidermis (Figure 6). 
However, more recent evidence hints, for example,  that epidermal stem 
cells might in fact be the cell of origin (Tilling 2012). Even though the cell of 
origin in MCC has been widely disputed and remains an open debate, Merkel 
cell carcinoma has become the most applied term.  
 
2.2.1 Epidemiology 
 
UV radiation is the most important exogenous predisposing factor for MCC 
(Lunder 1998, Popp 2002, Wong 2015). Thus, over 50% of the tumors occur 
in the sun-exposed head and neck region (Agelli 2010, Kukko 2012, Albores-
Saavedra 2010). MCC primarily manifests in the elderly population, the mean 
age of the patients being around 75 years (Agelli 2010, Kukko 2012). 
Additionally, it infrequently appears in the younger population with 
immunocompromising conditions including, an HIV-infection or an organ 
transplant recipient associated with immunosuppressive treatment (Sahi 
2010, Koljonen 2009b). The male-to-female ratio is somewhat controversial, 
as some population-based studies have reported male predominance 
(Hodgson 2005, Allen 2005) and others either found no difference (Lyhne 
2011) or claimed a minor female predominance (Kukko 2012). MCC patients 
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have a higher risk for developing another cancer and vice versa. The elevated 
risk for Chronic lymphocytic leukemia and BCC is especially documented in 
Finnish MCC patients (Koljonen 2009a, Koljonen 2010). 
 
MCC is a relatively rare tumor. The incidence rate is highest in Australia, 
being 1.6/100 000 (age-standardized to USA standard population), probably 
due to strong, sustained sun exposure (Youlden 2014). In the USA, the 
incidence rate has been growing substantially and was 0.79/100 000 in 2011 
(not age-standardized) (Fitzgerald 2015). In Finland, there were 295 cases of 
Merkel cell carcinoma reported to the Finnish Cancer Registry from 1989 to 
2008. Accordingly, the age-standardized (World standard population) 
incidence was 0.11/100 000 for men and 0.12/100 000 for women (Kukko 
2012).  
 
MCC is an exceedingly aggressive form of cancer.  Around one-quarter of the 
cases have local lymph node involvement, while distant metastasis is found 
in 7-12% of MCC cases (Lebbe 2015, Harms 2016, Lemos 2010). Disease-
specific overall mortality is estimated at 33-46%, (Lemos 2010, Becker 2010) 
which surpasses the mortality rates of melanoma (Hodgson 2005, Grabowski 
2008).  
 
2.2.2 Histology 
 
Microscopic evaluation of hematoxylin and eosin stained MCC samples 
commonly illustrate spherical, small blue cells with hyperchromatic nuclei 
(Figure 3). The ratio of cytoplasm to nucleus is diminished (Bichakjian 2007). 
MCC cells embody neuroendocrine characteristics such as neurosecretory 
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granules seen in electron microscopy and expression of neuron-specific 
enolase  (Hitchcock 1988). There are three histologic subtypes of MCC: 
intermediate, small-cell and trabecular subtype (Ratner 1993, Jaeger 2012).  
Intermediate is the most common type (Figure 3), while trabecular is the 
rarest. The small-cell type resembles small-cell lung carcinoma; it is poorly 
differentiated and advances rapidly, as does the intermediate type (Jaeger 
2012).  
 
 
Figure 3. Microscopic view of intermediate type MCC. Hematoxylin & eosin staining.   Modified  
from (Jaeger 2012). 
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             2.2.3 Clinical presentation 
 
MCC typically presents as a nodular mass, the size of which can vary from 
millimeters to several centimeters. The tumor is located in the dermal layer 
of the skin and is often covered by intact epidermis. MCC may, however, 
ulcerate to the skin surface (Heath 2008). Typical macroscopic findings are 
displayed in Figures 4 and 5. MCC has a strong propensity to metastasize. 
The invasion of local lymph nodes is notably more common in MCC when 
compared to other malignant skin tumors (Prewett 2015). The most 
common sites of distant metastasis are distant lymph nodes, liver and lung 
(Kouzmina 2017). Beyond being a skin lesion, Merkel cell carcinoma can 
manifest in  unusual and curious ways. Examples of this are presented in 
Table 2. 
          
         Figure 4. Typical nodular MCC on eyebrow.                Figure 5. Ulcerated large MCC on the cheek            
              Courtesy of Dr. Virve Koljonen.                               and local metastasis on the neck. Courtesy of Dr. Virve Koljonen 
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   Table 2. This table presents rare and somewhat bizarre cases of MCC found in the literature. 
 
MCC mimicking cellulitis 49-year-old woman was treated with antibiotics for 
presumed osteomyelitis of the left fifth digit. 
Debridement of the digit after failure of antibiotic 
treatment revealed MCC and patient was further 
diagnosed with metastatic disease. (Safa 2018) 
Pleural fluid metastasis of 
MCC 
68-year-old woman was first diagnosed with MCC 
of the buttocks which was surgically excised. 
However, the disease relapsed with vast nodal 
spread. 2-years after the primary excision, 
metastasis to left axillary lymph nodes and pleural 
fluid was discovered. (Rhee 2018) 
Intra-thoracic MCC 64-year-old woman presented with large intra-
thoracic mass which was biopsied and established 
as MCC. She was treated for vulvar MCC 10-years 
earlier but no local recurrence was present. (Kong 
2017) 
Secondary MCC on skin graft 
donor site  
92-year-old male was diagnosed with MCC on his 
left cheek which was excised and full thickness skin 
graft was applied. 4-years later, secondary MCC on 
the supraclavicular donor site was diagnosed. 
(Aloraifi 2017) 
Testicular MCC 66-year-old male presented with left testicular 
swelling and was diagnosed with MCC of the testis. 
3-months later tumor metastasized to right testis. 
No primary skin lesion was identified. (Mweempwa 
2016) 
Anal canal MCC 42-year old woman was diagnosed with MCC on the 
anal canal. She died 13 months after diagnosis due 
to metastatic disease. (Paterson 2003) 
Subcutaneous MCC  63-year-old woman presented with subcutaneous 
mass of the left arm which was diagnosed as MCC 
and completely confined to subcutis and showed 
no dermal or epidermal involvement in MRI scan or 
histopathologic examination. (Huang 2005) 
Oral MCC 28-year old male was diagnosed with oral MCC in 
alveolar mucosa extending to floor of the mouth 
and submandibular lymph node metastasis. 
Hemimandibulectomy and neck dissection was 
performed followed by radiotherapy. (Prabhu 
2010)  
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2.2.4 Diagnosis and staging 
 
The diagnosis of MCC begins with surgical excision of the suspected skin 
lesion with 1-2 mm clinical margins, or if the location or size of the tumor is 
challenging, a punch biopsy may be used. A pathologist then performs the 
histological examination of the tumor sample combined with 
immunohistochemical staining. Cancers that can cause challenges in 
differential diagnostics include small-cell lung carcinoma, carcinoid tumor, 
malignant lymphoma, and small-cell melanoma. Positive staining of 
Cytokeratin-20 (CK20), which is fairly specific for MCC among skin tumors, 
and negative staining of Thyroid transcription factor 1 (TTF-1) is typically 
required for MCC diagnosis. The absence of TTF-1 expression differentiates 
MCC from small-cell lung carcinoma (Dancey 2006).    
 
The first adequate staging system for MCC was produced by the American 
Joint Committee on Cancer (AJCC) in 2009 (Edge 2010). Since then, an 
updated staging system was presented in the 8th edition of the AJCC cancer 
staging manual, replacing the previous system as of January 2018 (Harms 
2016). In this system, the size of the primary tumor, invasion to the local 
lymph nodes and presence of distant metastases are taken into account. 
Stage is defined as either clinical or pathological depending on whether the 
evaluation is based on clinical examination, as for example lymph node 
palpation, or microscopic examination by a pathologist. Table 3 presents the 
system in detail.  
 
Due to the high tendency to invade and metastasize, pathological 
examination of the local lymph nodes via the Sentinel lymph node biopsy 
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(SLNB) is recommended in all cases of MCC (Lebbe 2015). About 30% of MCC 
cases that clinically present lymph node negative  show micrometastasis in 
SLNB. Thus, SLNB aids considerably in staging MCC precisely and planning 
adequate treatment (Lebbe 2015, Prewett 2015) 
 
 
 
 
Table 3. The new TNM classification and staging of MCC according to AJCC cancer staging manual. 
(Harms 2016) Reproduced with permission from Springer nature.  
 
  Clinical stage groups 
(cTNM) 
  Pathological stage groups 
(pTNM) 
T N M T N M 
0 Tis N0 M0 0 Tis N0 M0 
I T1 N0 M0 I T1 N0 M0 
IIA T2–3 N0 M0 IIA T2–3 N0 M0 
IIB T4 N0 M0 IIB T4 N0 M0 
III T0–4 N1–3 M0 IIIA T1–4 N1a(sn) or 
N1a 
M0 
        T0 N1b M0 
      IIIB T1–4 N1b–3 M0 
IV T0–4 Any N M1 IV T0–4 Any N M1 
        
T N M 
Tx, primary 
tumor cann
cNx, regional 
lymph  nodes 
cannot be 
clinically  asse
pNx, regional lymph 
nodes cannot 
be  assessed (e.g., 
previously removed 
M0,  no distant  metastasis 
M1,  distant  metastasis 
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T N M 
ot be 
assessed 
T0, no 
primary 
tumor 
Tis, in 
situ  primar
y tumor 
T1, primary 
tumor 
≤2 cm 
T2, primary 
tumor 
>2 cm  but 
≤5 cm 
T3, primary 
tumor 
>5 cm 
T4, primary 
tumor  inva
des fascia, 
muscle, 
cartilage,  o
r bone 
ssed (e.g., 
previously 
removed  for 
another 
reason, body 
habitus) 
cN0, no 
regional 
lymph  node 
metastasis by 
clinical 
or  radiologica
l evaluation 
cN1, 
clinically  dete
cted regional 
nodal 
metastasis 
cN2, in-
transit  metast
asis without 
lymph 
node  metasta
sis 
cN3, in-
transit  metast
asis with 
lymph 
node  metasta
sis 
for another  reason) 
or not removed for 
pathological 
evaluation 
pN0, no regional 
lymph node 
metastasis  detected 
on pathological 
evaluation 
pN1a(sn), clinically 
occult 
nodal  metastasis 
identified only by 
sentinel lymph 
node  biopsy 
pN1a, clinically 
occult regional 
lymph  node 
metastasis following 
lymph node 
dissection 
pN1b, clinically or 
radiologically  detect
ed regional lymph 
node 
metastasis,  patholog
ically confirmed 
pN2, in-transit 
metastasis without 
lymph  node 
metastasis 
pN3, in-transit 
metastasis with 
lymph  node 
metastasis 
 M1a,  metastasis to  distant 
skin,  distant  subcutaneous 
 tissue, or  distant 
lymph  nodes 
 M1b,  lung 
 M1c,  all other  distant sites 
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2.2.5 Treatment 
 
MCC treatment is based on wide surgical excision of the primary tumor with 
clear margins. No extensive studies have been conducted to evaluate 
sufficiency of the margins, but 1-2cm of healthy tissue is the most customary 
practice (Lebbe 2015, Prewett 2015). Definitive wide excision (re-excision) is 
often done after the initial diagnostic excision and pathological confirmation 
of MCC. Direct closure of the wound is desirable, although skin grafts, local 
skin flaps or even microvascular flaps are occasionally necessary for 
reconstruction. When planning the reconstruction, the need for following 
adjuvant treatment such as local radiation should be taken into account.  
 
Mohs micrographic surgery, developed in the 1930s, is occasionally utilized 
overseas for primary treatment, and it might be beneficial in reaching clear 
margins, especially in areas where preservation of tissue is crucial (Tai 2013). 
In this technique, tissue is removed gradually, and each resection is 
microscopically examined by a pathologist for tumor cells and indicating a 
demand for further removal which continues until the removed tissue is free 
of tumor cells (Mikhail 1999). In a recent review study, Mohs surgery and 
traditional wide excision appeared equally efficient in treating local MCC 
(Stage I-II). There was no difference in overall survival or histological 
presence of residual tumor in surgical margins between the two modalities 
(Singh 2018). However, In Finland, Mohs surgery has not been established in 
the treatment of MCC, and wide excision with 1-2 cm margins remains as the 
treatment of choice (Personal communication with Dr. Koljonen and Dr. 
Koskivuo).  
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Radiotherapy has been used as a primary treatment without surgical 
intervention for local MCC. However, surgery has a superior impact on 
survival and remains the cornerstone of initial treatment (Wright 2018). 
Furthermore, adjuvant radiotherapy to the surgical excision site is 
recommended due to its positive effect on survival in retrospective studies 
(Lebbe 2015, Fiedler 2018). After initial tumor removal, lymph node 
dissection or local radiotherapy to the nodal area is rational in cases where 
SLNB is positive or has not been carried out (Lebbe 2015, Prewett 2015).  
 
For advanced MCC, chemotherapy is employed, and response is often 
desirable. However, the recurrence is frequent. The most utilized 
pharmaceuticals are carboplatin or cisplatin coupled with etoposide 
(Nghiem 2017, Cassler 2016). In addition to these traditional 
chemotherapeutics, In 2016 a human anti–PD-L1 monoclonal antibody 
called Avelumab became the first treatment approved by the US Food and 
Drug Administration (FDA) for patients with stage IV MCC (Kaufman 2016, 
Kaufman 2018). Avelumab targets the transmembrane protein Programmed 
death-ligand-1 (PD-L1) that forms a complex with programmed cell death-1 
receptor (PD-1) and inhibits T cell activity. Avelumab prevents this T cell 
inhibition by blocking the formation of PD-L1/PD-1 complex and therefore 
preserves immune response. It has been suggested that cancers can evade 
the host’s immune system via upregulation of PD-L1 (Dong 2002, Sheppard 
2004, Thompson 2004). On a one-year follow-up study, Avelumab seems to 
have durable a response in patients that underwent at least one previous 
line of chemotherapy for stage IV MCC (Kaufman 2018). In addition to 
Avelumab, the PD-1 inhibitor Pembrolizumab has shown encouraging and 
durable response rates in advanced MCC as a first-line treatment and just 
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recently in early 2019 became approved by the FDA in treatment of 
metastatic MCC (Nghiem 2016, Nghiem 2019). 
 
 
2.2.6 Merkel cell polyomavirus 
 
In 2008, Feng et al. discovered the Merkel cell polyomavirus (MCV) from the 
tumor tissue of MCC patients (Feng 2008). The virus was clonally integrated 
into MCC genome, thus suggesting infectious etiology to MCC. Further 
studies have demonstrated that MCV is present in approximately 80% of 
MCC tumors (Feng 2008, Sihto 2009, Becker 2009, Garneski 2009, Kassem 
2008, Mangana 2010).  
 
Polyomaviruses are small, double-stranded DNA viruses that are very 
common and most of the time do not cause disease in humans. As of 2016, 
13 polyomaviruses with human hosts have been identified (Polyomaviridae 
Study Group of the International Committee on Taxonomy of Viruses 2016, 
Kean 2009). MCV is the first and yet only polyomavirus known to cause 
cancer, although five other polyomaviruses are associated with human 
disease (Table 4). Like all polyomaviruses, the MCV genome encodes so-
called T antigens. MCV infected MCC cells harbor truncating mutations in 
viral Large T antigen (LT) genomic sequence, which makes the virus incapable 
of replicating, and thus viruses cannot propagate outside of the infected cell. 
A functioning viral replication process would also facilitate cell death in 
tumor cells. These facts indicate that MCV infection occurs before clonal 
expansion of MCC tumor cells, and truncating LT mutations are required to 
sustain tumor growth (Shuda 2008). Furthermore, T antigens are necessary 
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for MCV infected MCC to maintain growth, because inhibiting T antigens 
trigger death of MCV-positive MCC cell lines (Houben 2010).  
 
It has been suggested that with improved detection methods, MCV can be 
found in all MCC tumors (Rodig 2012). In fact, MCV DNA can occur in low 
quantities on normal or malignant cells and is in that case considered an 
occupant virus without a role in oncogenesis (Shuda 2009, Loyo 2010, 
Foulongne 2010). MCV tumors that harbor oncogenic, integrated MCV 
genome express LT, which can be demonstrated with mouse monoclonal 
antibody CM2B4. Thus, the presence of a sufficient copy number of MCV 
DNA is required for the MCC tumor to be determined MCV-positive (Sihto 
2009, Higaki-Mori 2012, Bhatia 2010a, Bhatia 2010b).  
 
Table 4. In addition to MCV, five other human polyomaviruses are known to have a disease 
correlate. 
Polyomavirus Associated disease 
Trichodysplasia spinulosa 
polyomavirus 
Trichodysplasia spinulosa (DeCaprio 2013) 
BK polyomavirus Polyomavirus associated nephropathy (DeCaprio 
2013) 
JC polyomavirus Proggressive multifocal leukoencephalopathy 
(DeCaprio 2013) 
Human polyomavirus 6 Pruritic and dyskeratotic dermatosis (Nguyen 2017) 
Human polyomavirus 7 Epithelial hyperplasia (Nguyen 2017) 
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2.2.7 MCV-positive MCC 
 
The majority of MCCs (80%) embodies MCV infection and is consequently 
called MCV-positive MCC. MCV-positive MCC is associated with a better 
outcome than MCV-negative MCC (Moshiri 2017, Sihto 2009, Sihto 2011, 
Andres 2009). These tumors tend to be located on a limb more often than 
MCV-negative, and express tumor suppressor RB1 (Sihto 2009, Sihto 2011).  
 
Pathogenesis of MCV-positive MCC has been under tremendous research 
since the discovery of MCV. A major oncogenic factor is inactivation of tumor 
suppressor RB1 by the LT antigen  (Borchert 2014). It has been demonstrated 
in vitro and in xenograft models that inactivation of RB1 by sequestration is 
necessary for MCV-positive MCC to maintain growth (Houben 2012). 
In addition to the LT antigen, MCV-positive MCC express Small T antigen (ST). 
Oncogenic properties of the ST antigen are established in murine models, 
and are believed to initiate malignant transformation while the LT antigen 
sustains it (Shuda 2015, Verhaegen 2015). Recent study reported that the ST 
antigen binds to MYCL proto-oncogene and unites it to the histone 
acetyltransferase and chromatin remodeling complex, named as EP400 
complex (Cheng 2017). The ST-MYCL-EP400 complex binds to specific gene 
promoters, activates their expression and promotes oncogenesis. MYCL and 
EP400 are necessary for MCV-positive MCC cell lines to maintain viability 
(Cheng 2017).  
 
MCV-positive MCC tumors are associated with a high number of tumor 
infiltrating lymphocytes (TILs) which refer to better survival (Sihto 2012). PD-
L1 expression in MCC seems to be bound to MCV-positive tumors, and PD-
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L1 positivity associates with a high number of TILs, suggesting that immune 
response promotes PD-L1 expression in the presence of MCV (Lipson 2013). 
 
 
2.2.8 MCV-negative MCC 
 
MCV-negative tumors comprise nearly 20% of MCC cases and they are more 
aggressive, having a greater risk to metastasize and cause death (Moshiri 
2017). The pathogenesis of MCV-negative MCC is more uncharted than is 
MCV-positive MCC. Studies have shown that MCV-negative tumors entail a 
remarkably higher mutational burden, and UV light associated mutations are 
especially frequent  (Wong 2015, Goh 2016, Harms 2015, Cimino 2014). 
 
 
Loss of RB1 expression is characteristic for MCV-negative MCC, but the 
underlying mechanism is not completely understood (Bhatia 2010a, Sihto 
2011). However, deletions of RB1 locus are observed more frequently in 
MCV-negative MCC (Paulson 2009, Sahi 2014, Van Gele 1998, Larramendy 
2004). In addition to RB1 deletions, TP53 mutations are seen more 
frequently in MCV-negative MCC tumors (Sihto 2011). TP53 is a gene 
encoding for a well-established tumor suppressor protein p53. It is estimated 
that over 50% of human cancers harbor TP53 mutations (Hollstein 1991).  
 
In MCV-negative MCC there are fewer TILs than in MCV-positive tumors, but 
when present the number of TILs associates with a better outcome, also in 
MCV-negative tumors, and correlates to PD-L1 positivity (Sihto 2012). In the 
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tumor series of Lipson et al. all of the MCV-negative tumors were PD-L1 
negative (Lipson 2013). 
 
 
 
Figure 6. Figure presents the simplified normal skin structures and main risk factors for 
MCC; Merkel cell polyomavirus (MCPyV) on the left and UV radiation on the right. MCC 
tumor is growing in the dermis. Potential cells of origin are present; Merkel cell, epidermal 
stem cell and pre-B cell. (Becker 2017) Reproduced and modified with permission from 
Springer Nature.  
 
 
 
 
 
 
 
 
  34 
2.3 Cancer genetics 
 
2.3.1 Gene mutations and cancer 
 
Mutations are persistent alterations of the nucleotide sequence of the DNA. 
Mutations arise from DNA damage caused by environmental factors such as 
radiation and irritant chemicals, or from defects in the DNA replication 
process. Mutations can be categorized into minor changes comprising one 
or a few nucleotides and larger alterations that affect large portions of 
nucleotide sequence. 
 
The smallest mutational change in the DNA is a point mutation, which means 
that a single nucleotide has been deleted, substituted with another 
nucleotide or a new nucleotide has been inserted in the genomic sequence 
(Yi 2018). During the translation process, the nucleotide sequence is 
decoded by the codons, triplets of nucleotides that code for one amino acid, 
to form an amino acid chain, which after further modification forms a 
protein. The alteration of single nucleotide in the codon can transform the 
amino acid which that codon encodes for and thus leads to the formation of 
a defective protein. This type of point mutation is called a missense 
mutation. Another type of point mutation is silent mutation, which means 
that the change in the nucleotide sequence does not alter the amino acid 
that is decoded, and therefore has no effect on the created protein. 
Furthermore, a point mutation can convert a normal codon into a stop codon 
that terminates the translation of an amino acid chain. This type of 
truncating point mutation is called a nonsense mutation.  
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Tumor suppressor genes protect the cells from uncontrolled cell 
proliferation and cancer formation. Tumor suppressors often avert cell cycle 
progression or promote apoptosis in response to DNA damage. Mutation in 
a tumor suppressor gene can cause oncogenic transformation of the cells if 
the mutation distorts the translation of normal functioning protein. One of 
the key tumor suppressor genes in the human genome is the RB1 gene. The 
tumor suppressing function of RB1 mainly results from its inhibitory effect 
on the transcription of genes required in the S-phase of the cell cycle. This 
effect is mediated by inactivation of the transcription factor E2F (Du 2006). 
Dysfunction of RB1 is present in many cancers, although it is named due to 
its relationship with retinoblastoma, cancer of the retina (Murphree 1984).  
 
 
A proto-oncogene is a gene that if mutated, can transform to an oncogene 
which has properties that promote malignant cell growth. Mutation of a 
proto-oncogene can cause constant abnormal expression of the gene and 
high activity of the coded protein that promotes cell growth and thus 
contributes to oncogenesis (Todd 1999). Typical examples of such proto-
oncogenes are genes belonging to the RAS subfamily. Proteins they encode, 
for example KRAS, function as mediators in various signal transduction 
cascades and mutations that cause high expression or constant activation of 
these proteins support cancer formation (Bos 1989).  
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2.3.2 Chromosomal aberrations and cancer 
 
Alterations in the chromosomal structure can result in abnormal expression 
of multiple genes. Translocation means that parts of different chromosomes 
are rearranged to form hybrid chromosomes. Translocation can be balanced 
where there is no loss of genetic information; the exchange of genetic 
information is equal between the affected chromosomes. Alternatively, a 
translocation can be unbalanced with either loss of genes or gain of extra 
genes. Sometimes, translocation results in the formation of a fusion gene 
with oncogenic properties. The best-known fusion gene is the BRC-ABL1, 
described first in chronic myelogenous leukemia (CML) and known as the 
Philadelphia chromosome. It consists of balanced and reciprocal exchange 
of chromosomal parts between chromosomes 9 and 22, which leads to 
coding of fusion protein that is a constantly active tyrosine kinase, facilitating 
continuous cell proliferation (Melo 1996). In addition to translocations, 
chromosome abnormalities include deletions, duplications and inversions.  
Deletion means that a part of a chromosome is lost, whereas in duplication 
a part is multiplied. When a chromosome portion has first detached and then 
reattached inversely, the alteration is called an inversion. All these structural 
abnormalities are a result of unsuccessful cell division. 
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2.3.3 Cancer genes 
 
2.3.3.1 Anaplastic lymphoma kinase  
 
Studies on anaplastic large-cell lymphoma (ALCL) indicated that a 
chromosomal translocation is frequently present in ALCL samples.   It was 
discovered that the translocation led to the formation of a fusion gene that 
consisted of a nucleophosmin (NPM) gene and a tyrosine kinase gene, later 
named the anaplastic lymphoma kinase gene (ALK). The resulting fusion 
protein is the oncogenic driver in 60% of the ALCL cases (Morris 1994). 
Another known fusion related to ALK is the EML4-ALK fusion gene that 
accounts for 3-5% of non-small-cell lung cancers (NSCLC) and also occurs in 
other cancers such as colorectal adenocarcinoma and breast carcinoma 
(Soda 2007, Lin 2009). The fusion of ALK with another gene leads to 
overexpression of ALK that promotes cancer formation. In addition to 
chromosomal translocation, ALK can be overexpressed, in result of mutation 
of the ALK gene, which is apparent in some thyroid cancers (Murugan 2011). 
An ALK inhibitor, crizotinib, has received FDA approval for treatment of 
NSCLC, and there are multiple inhibitors currently undergoing clinical trials.  
 
2.3.3.2 Epidermal growth factor receptor  
 
The epidermal growth factor receptor (EGFR) is a cell membrane receptor 
for extracellular protein ligands that belong to the epidermal growth factor 
family. These ligands include the epidermal growth factor (EGF) and the 
transforming growth factor  (TGF). Binding of ligand to EGFR initiates its 
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intrinsic intracellular tyrosine kinase activity which triggers downstream 
signaling cascades that ultimately lead to DNA synthesis and cell 
proliferation (Oda 2005, Yarden 1987). Mutations in the EGFR gene that 
induces overexpression or overactivity of EGFR have been reported in many 
types of cancer, for example NSCLC, prostate carcinoma and anal squamous 
cell carcinoma (Peraldo-Neia 2011, Walker 2009, Murray 2006). Many EGFR 
inhibitors are currently in clinical use as cancer treatment (Liang 2014). In 
NSCLC, occurrence of EGFR mutations as well as expression of EGFR predicts 
responsiveness to EGFR inhibitor treatment (Brandao 2012, Han 2005, 
Huang 2004).  
 
 
2.3.3.3 Enhancer of zeste homolog 2  
 
Enhancer of zeste homolog 2 (EZH2) is an enzyme that catalyzes DNA 
methylation and thus induces heterochromatin formation and repression of 
gene function (Vire 2006). Many types of cancer harbor overexpression of 
EZH2. Its oncogenic effect originates from inactivation of important tumor 
suppressor genes (Zingg 2015, Kim 2016). In renal cell carcinoma, 
overexpression of EZH2 is suggested to predict poor prognosis (Lee 2012). 
Inhibitors of EZH2 are currently in development, and their use in cancer 
treatment is an active area of research (Kim 2016). 
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        2.3.4 MicroRNA and cancer 
 
MicroRNAs (miRNA) are small non-coding RNA molecules that function as 
post-transcriptional regulators of gene expression. This group of RNA 
molecules were acknowledged in the early 2000s and is an emerging field in 
medical research. Abnormal miRNA expression can consequently modify 
expression of important oncogenes or tumor suppressors to promote 
malignant growth. miRNAs regulate gene expression by binding to 
messenger RNA (mRNA) and prohibit its translation to a functional protein. 
The human genome encodes hundreds of miRNAs, all of which have multiple 
target genes. Further, one gene can be regulated by many miRNAs (Williams 
2008). The first human cancer that was associated with aberrant miRNA 
expression is chronic lymphocytic leukemia (CLL). Since then, miRNA 
profiling of various cancer types has expressed that abnormalities in miRNA 
expression are frequent in cancer. miRNAs are expected to be applicable 
particularly well in cancer screening and as prognostic factors (Reddy 2015). 
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3 AIMS OF THE STUDY 
 
The aim of this study was to examine molecular alterations in 
Merkel cell carcinoma tumor samples utilizing methods of 
modern cancer research with special  interest on distinction of 
polyomavirus negative and positive MCC. A further aim was to 
assess the correlation of molecular aberrations and clinical 
characteristics of MCC patients with emphasis put on disease 
progression.  
 
Specified aims were to: 
 
1) Explore and compare the MicroRNA profiles of MCV-negative 
and MCV-positive MCC tumors. (STUDY I) 
 
2) Analyze the mutational patterns in MCV-negative and MCV-
positive MCC tumors by targeted Next-generation sequencing. 
(STUDY II) 
 
3) Quantify mRNA expression of 50 cancer-related genes in MCC 
by targeted NGS. (STUDY III) 
 
4) Determine expression of ALK, EGFR and EZH2 and their 
association to MCV status in MCC tumors and evaluate clinical 
significance of the proteins. (STUDY IV) 
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4 MATERIALS AND METHODS 
 
4.1 Merkel cell carcinoma samples and clinical data 
 
The Ethics Committee of Helsinki University Hospital approved the study. 
The Ministry of Health and Social Affairs granted permission to collect 
patient data and the National Authority for Medicolegal Affairs to collect and 
analyze tissue samples. 
 
Formalin-fixed, paraffin-embedded (FFPE) MCC tumor samples were 
collected from our nationally gathered pool of around 270 MCC samples 
(years 1979 – 2013) in the pathology archives. MCC diagnoses were 
confirmed by morphology compatible with MCC in microscopy and by 
immunohistochemistry positive for CK-20 (DakoCytomation, Glostrup, 
Denmark) and negative for TTF-1 (Novocastra reagents, Leica Biosystems, 
Wetzlar, Germany). MCV-detection was done previously by quantitative PCR 
and proportioned to reference the gene protein tyrosine phosphatase 
gamma receptor gene (PTPRG). The sample was considered positive if the 
MCV DNA copy number per reference gene was greater than 0.1. The 
process is described in detail elsewhere (Sihto 2009). Tissue micro arrays 
(TMA) were constructed from FFPE tumor samples. 0.6-mm tissue area of 
each tumor sample was inserted into an empty well on the tissue array block 
(IV).  
 
Clinical details were extracted from clinical files and hospital records. 
Gathered details included patient age, sex, primary tumor location, tumor 
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size, information about development of metastasis, date of diagnosis and 
date of death from MCC. 
 
4.2 DNA and RNA extraction 
 
DNA was extracted from FFPE samples according to the manufacturer’s 
instructions with a QIAamp DNA Mini Kit (250) (QIAGEN, Hilden, Germany). 
DNA concentration was measured with a Qubit® 2.0 fluorometer (Thermo 
Fisher Scientific, Waltham, MA, USA) (II). 
 
Extraction of total RNA, including miRNA was carried out utilizing a miRNeasy 
mini Kit (QIAGEN) according to the manufacturer’s instructions. RNA was 
quantified by either The NanoDrop-1000 Spectrophotometer (Thermo 
Fisher Scientific) (I) or Qubit® 2.0 fluorometer (Thermo Fisher Scientific) (III). 
Quality of RNA was measured by either Agilent 2100 Bioanalyzer (Agilent 
Technologies, Palo Alto, CA, USA) (I) or 2200 TapeStation System in 
combination with RNA ScreenTape assay (Agilent Technologies) (III). 
 
 
4.3 Microarrays and miRNA target prediction (Study I) 
 
Microarrays were constructed with the miRNA Complete Labeling and 
Hybridization kit protocol version 2.4 (Agilent Technologies). Hybridization 
of RNA samples was performed on Agilent’s miRNA Microarray System V16 
(1205 human and 144 human viral miRNAs, Sanger miRBase 16.0). The 
microarrays were washed with the manufacturer’s washing buffers. Arrays 
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were scanned with Agilent’s Feature Extraction (v.11.0.1.1.), and default 
parameters were applied to extract the data.  
 
The following databases were employed to search for predicted mRNA 
targets of the miRNAs: TargetScan (http://www.targetscan.org), miRanda 
(http:// www.microrna.org/microrna/home.do), mirTarget2 (http:// 
mirdb.org/miRDB), Tarbase (http://diana.cslab.ece.ntua.gr/ tarbase), 
miRBase target prediction database (http://www. mirbase.org/), and PICTAR 
(pictar.mdc-berlin.de). To exclude false positives, only those mRNA targets 
that were predicted by at least four of the six programs were accounted for. 
Predicted mRNA targets were screened by Chipster v1.4.7 
(http://chipster.csc.fi/) for significant enrichment of overrepresented 
pathways in the ConsensusPathDB (CPDB) by the hypergeometric test (p < 
0.05). 
 
 
4.4 Quantitative Real-Time PCR (Study I) 
 
To validate the microarray results. Reverse transcription of the RNA was 
executed with a miScript II RT Kit (50) (QIAGEN) according to the 
manufacturer’s instructions. Quantitative Real-Time PCR (qRT-PCR) was 
conducted with a miScript SYBR Green PCR Kit (QIAGEN) and a LightCycler 
480 (Roche Diagnostics GmbH, Mannheim, Germany) according to the 
manufacturers’ protocols.  
Amplification primers for miRNAs (miR-34a, miR- 30a, miR-181d, miR-142-
3p, and miR-1539) and U6 were purchased from QIAGEN. Data was 
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normalized according to U6 expression. Duplicate RNA samples with a 
negative control (no template of cDNA) were included in every PCR run. 
Potential nonspecific amplification was assessed with melting curve analysis.  
 
The ΔΔCt method was used for relative quantification of miRNA expression. 
The relative quantity (RQ) for each miRNA, compared with the quantity of 
U6, was calculated. Mean and median RQs for MCV-positive and MCV-
negative tumors were calculated. Expression data of miRNAs was presented 
also as fold change (fold change = log 2 RQ). 
 
 
4.5 Next-generation sequencing (Studies II and III) 
 
Mutation and RNA expression projects (II and III) were performed by 
amplicon-based next-generation sequencing (NGS) using Ion Torrent 
technology (Thermo Fisher Scientific). The Ion AmpliSeq Cancer Hotspot 
Panel v2 (Thermo Fisher Scientific) and the Ion AmpliSeq RNA Cancer Panel 
(Thermo Fisher Scientific) were utilized to amplify target amplicons in 50 
cancer-related genes and mRNA.  
 
The DNA libraries were constructed from 10ng of DNA with the Ion 
AmpliSeq Library Kit 2.0 (Thermo Fisher Scientific). The RNA libraries were 
constructed from 20ng of RNA with the Ion AmpliSeq RNA Library Kit 
(Thermo Fisher Scientific). All the libraries were barcoded with the Ion 
Xpress Barcode Adapter Kit (Thermo Fisher Scientific) and the library 
concentrations were measured using the Qubit 2.0 Fluorometer. 
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Templates for sequencing were prepared using either the Ion PGM 
Template OT2 200 Kit (II) or the Ion PGM Hi-Q OT2 Kit (III) and Ion 
OneTouch 2 System (Thermo Fisher Scientific). Ion Sphere particles were 
enriched with Ion OneTouch ES (Thermo Fisher Scientific) and loaded onto 
Ion 316 Chip (II) or to Ion 318 Chip (III). Sequencing was performed on 
the Ion Torrent PGM System with the Ion PGM Sequencing 200 Kit v2 (II) 
and the Ion PGM Hi-Q Sequencing Kit (III). 
 
To analyze the mutation data (II), the Ion Torrent Suite Software 4.0.2 and 
the Torrent Variant Caller Plugin 4.0 were applied for signal processing, base 
calling, sequence alignment, variant analysis, and hotspot mutation analysis. 
The aligned reads were visually inspected with the integrative Genomics 
Viewer (IGV v2.2, Broad Institute, Cambridge, MA, USA). In silico evaluation 
of the effect of nucleotide variation on the protein function was executed 
with SIFT and PROVEAN. 
The average sequencing mean depth for all tumor samples was 1542X, with 
an average of 95% uniformity across targets. To rule out possible technical 
errors, the quality score threshold for variant calling was set at Q30. 
 
For the RNA expression data (III), the Coverage Analysis plugin was used to 
create amplicon counts. The amplicon count data created was imported into 
a Chipster (http://chipster.csc.fi/index.shtml) for further expression 
analysis.  Expression differences between tumor and normal skin tissue and 
MCV-positive and MCV-negative tumors were analyzed with DESeq2. 
Differently expressed genes were determined from adjusted p-values and 
log2 fold changes. To control for false positives, the p-values were corrected 
for multiple testing and the adjusted p-value or FDR (false discovery rate) 
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calculated with Benjamini-Hochberg correction. An average of 344,458 reads 
(after quality check) were obtained for each sample with an average of 95% 
on target. 
 
 
4.6 Fluorescence in situ hybridization (Study III) 
 
2 μm thick FFPE tumor sections fixed on microscopic slides were 
deparaffinized, pretreated with protease and hybridized with Vysis LSI ALK 
Dual Color Break Apart FISH probes according to the manufacturer’s 
guidelines (Abbott Molecular Inc., Des Plaines, IL, USA). Slides were 
interpreted under a fluorescence microscope. The presence of at least one 
green and orange signal pair split apart by ≥2 signal diameters (pair-signal 
type fusion), or a single orange without corresponding green signal (single-
signal type fusion) was required to determine a cell to be ALK gene 
rearrangement positive. The cells were defined as ALK rearrangement 
negative if they had fused or if they had a close orange and green signal.  
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4.7 Immunohistochemistry 
 
For immunohistochemistry, three- or five-micron sections were cut from the 
FFPE samples and processed further. In study II and III, staining for EGFR 
(clone 31G7 Invitrogen, Waltham, MA, USA) and ALK (clone 5A4, 
NovocastraTM, Leica Biosystems, Wetzlar, Germany and clone D5F3 
Ventana/Roche, Tucson, AZ, USA) was performed on the BenchMark XT 
(Ventana/Roche). Detection of EGFR was with the ultra VIEW Universal DAB 
Detection Kit (Ventana/Roche) and ALK detection with OptiView (760–700, 
Roche) amplification kit (Roche/Ventana, 760–099).  
 
In study IV, the ALK (clone D5F3, Roche 790-4794) and EGFR (clone 5B7, 
Roche 790-4347) stainings were performed with the Ventana Benchmark 
Ultra instrument (Roche), while the EZH2 staining (clone 11/EZH2, BD 
Transduction 612666, USA) was performed in the LabVision immunostainer 
(Labvision, CA, USA). Detection of ALK and EGFR was with OptiView, while 
EZH2 was detected with the polymer-based detection system (Envision, 
K5007, Agilent, USA). All of the IHC slides were finally stained with 
hematoxylin (Mayer, S3099, Dako, Glostrup, Denmark) and then assessed 
with a microscope by two researchers (II, III and IV). 
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4.8 Statistical analysis 
 
Statistical analysis of the microarray data was accomplished via GeneSpring 
GX Analysis Software v11.0.2 (Agilent). The data was preprocessed by log 2 
transformation, and all arrays were normalized by the 75th percentile 
method. We excluded miRNAs that were absent in any of the samples or 
controls from further analysis. miRNAs not expressed in at least 100 % of one 
group of samples were excluded. The significance of differential expression 
between every two groups of samples was estimated by t test for those 
miRNAs with at least a 2.0-fold reduced or increased mean expression level 
between the two groups. Expression of mirRNAs was considered to differ 
significantly when the adjusted p value (q value) was <0.2 (Benjamini 
correction for multiple testing) (I). To determine statistically significant 
differences in miRNA expression between the defined MCC subgroups, the 
students’ t test and Mann- Whitney U test were applied. P values of less than 
0.05 were considered statistically significant (I).  
 
The relationship between mutation count and MCV status was evaluated 
with the Mann–Whitney U-test (II). The correlation of tumor location, size as 
well as patient’s age with the MCV status was examined with Fisher’s test 
(II). Statistical analysis to correlate protein expression to MCV status and 
clinical data was with the Chi-Squared and Fisher’s exact test (IV). To analyze 
the relationship between protein expression and MCC-specific survival, the 
Kaplan-Meier method and the log rank test were utilized. MCC-specific 
survival was calculated from the date of diagnosis to the date of death from 
MCC (IV). 
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5 RESULTS  
 
5.1 Patients 
 
Patients involved in studies I, II and III were selected from a cohort of 32 
patients (16 MCV-positive and 16 MCV-negative), 17 patients were included 
in all three studies I, II and III. This cohort of 32 patients is presented in Table 
5. From these 32 patients, 9 (28%) were males while 23 (72%) were females. 
11 tumors (34%) were located in the head and neck region. The mean age of 
the patients was 79 years.  
 
Study IV included 112 MCC tumor samples in tissue micro arrays (TMA). 
From the 112 corresponding patients, 30 (27 %) were males and 82 (73 %) 
females. Over half of the tumors, 60 (54%) were located in the head and neck 
region. 31 tumors were MCV-negative (28%) and 81 MCV-positive (72%). The 
mean age of the patients was 78 years. Development of metastasis was 
reported in 28 out of 112 patients (25%), and the MCC-specific mortality rate 
was 20%. The clinical follow-up for these patients ended 12th of June 2013. 
 
5.2 MicroRNA profiles (Study I) 
 
Microarray was utilized for 15 MCV-positive and 13 MCV-negative MCC 
tumors and revealed five differently expressed miRNAs between the two 
cohorts. miR-34a, miR-30a, miR- 1539, and miR-142-3p were significantly 
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underexpressed, and miR-181d was overexpressed in MCV-negative tumors 
compared to MCV-positives.  
 
To validate the array results, we performed qRT-PCR on 14 MCV-positive and 
12 MCV-negative tumors, and confirmed underexpression of miR-34a, miR-
30a, miR-142-3p, and miR-1539 in MCV-negative tumors, although only the 
distinction of miR-34a was statistically significant. (p-value 0.0043, Mann-
Whitney test) (Figure 7) Regarding miR-181d, qRT-PCR and microarray 
provided conflicting results and therefore we did not reach conclusions 
about expression of miR-181d. In this study, miRNA expression did not 
correlate to the disease stage or survival. 
 
 
 
  
Figure 7. The relative expression of four miRNAs in MCV-positive and MCV-negative tumors 
by qPCR. (Veija 2015) Reproduced with permission from Springer Nature.  
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5.3 Gene mutations and RNA expression (Studies II and III) 
 
Mutational analysis was done with 15 MCV-negative and 12 MCV-positive 
tumors (II). 13 (48%) tumors harbored hotspot mutations in one or more of 
21 cancer genes that were included in the panel of 50 genes. MCV-negative 
tumors had a higher mutational burden (Not statistically significant, p-value 
= 0.24) and had mutations in 20 different genes, while MCV-positive tumors 
had them in only 5 genes. Mostly mutated genes were TP53 (4 MCV-negative 
and 3 MCV-positive), EGFR (4 MCV-negative and 2 MCV-positive), KIT (4 
MCV-negative and 1 MCV-positive), and PIK3CA (4 MCV-negative and 1 MCV-
positive). The frequency of hotspot mutations in MCV-negative and MCV-
positive tumors are shown in Figure 8. In addition, we found infrequent novel 
RB1 mutations only in MCV-negative tumors.  
Figure 8. Frequency of hotspot mutations in MCV-negative and MCV-positive tumors. Y-axis = 
number of tumors. 
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RNA expression analysis was executed for 13 MCV-positive and 13 MCV-
negative MCC tumors. (III) Significant overexpression of ALK, CDKN2A, EZH2 
and ERBB4 and underexpression of EGFR, ERBB2, PDGFRA and FGFR1 was 
evident in MCC tumors compared to normal skin regardless of the MCV-
status. (p-value <0.005 and log2 fold change of at least 2) ALK was the most 
highly expressed gene, while EGFR expression was the lowest. (fold change 
7,6 for ALK and -4.8 for EGFR) In addition, six genes MET, NOTCH1, FGFR3, 
SMO, JAK3 and NPM1 were differently expressed in MCV-positive and MCV-
negative tumors. 
Expression of ALK mRNA was seen in all 26 MCC cases, and expression was 
evidently high in 22 tumors. There was no difference in expression between 
MCV-positive and MCV-negative tumors.  Fluorescence in situ hybridization 
(FISH) was successfully carried for 21 tumors, but no ALK fusion was 
recorded. However, in five tumors there were indications of possible gain or 
polyploidy involving ALK.  
 
 
 
Table 5. This table presents the cohort of 32 MCC patients that were included in studies 
I, II and III. MicroRNA column states if the tumor was included (yes/no) in the study. In 
columns ALK NGS, IHC and FISH, na (not applicable) = not included in the study, + = 
positive expression/gain or polyploidy in FISH analysis, - = negative expression/no findings 
in FISH. (+) means weak positive expression in ALK IHC. 
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Patient age sex Primary 
tumor 
location 
Metastasis MCV    MicroRNA ALK NGS ALK 
IHC    
D5F3 
ALK FISH Genes 
with 
hotspot 
mutations 
1 90 female Right temple Right neck neg  yes na na na na 
2 68 male unknown Scalp pos  yes  +  +   - na 
3 80 female Posterior 
thigh 
Inguinal and 
axillary lymph 
nodes 
pos  yes  +  +   +  none 
4 59 male Thorax none pos  yes  +  +   - none 
5 72 female unknown none pos  yes  +  +   - na 
6 67 male left cheek none neg  yes na na na APC, EGFR, 
KIT, TP53 
7 81 female unknown none pos  yes  +  +   - na 
8 83 female Right arm none neg  yes  +  +   +  none 
9 85 female Left temple none neg  yes  -  -  - ATM, 
BRAF, 
CTNNB1, 
EGFR, 
ERBB4, 
KRAS, 
PIK3CA, 
PTEN, 
PTPN11, 
STK11, 
TP53, VHL 
10 90 female Forehead none pos  yes  +  +   - none 
11 71 male Right 
buttock 
none pos  yes  +  +   - EGFR 
12 95 female Left cheek none pos  yes  +  +   - none 
13 87 female Left 
shoulder 
Axillary 
lymph nodes 
pos  yes na na na none 
14 77 female Right cheek Mediastinum, 
pleura and 
brain 
neg  yes  +  +   - KIT 
15 79 female Right breast none neg  yes  +  +   - APC, 
CDKN2A, 
EGFR, 
FLT3, KIT, 
PTPN11, 
SRC 
16 72 female Calf Inguinal 
lymph nodes 
neg  yes  +  +   - CTNNB1, 
EGFR, KDR, 
KIT, KRAS, 
TP53 
17 57 female Right cheek none pos  yes na na na na 
18 78 male Neck Anal canal, 
pancreas 
neg  yes  +  +   - none 
19 79 male Left forearm none pos  yes  +  +   - none 
20 81 female Left upper 
back 
none neg  yes  +  +   +  none 
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5.4 Immunohistochemistry (Studies II, III and IV) 
 
 
5.4.1 ALK immunohistochemistry 
 
In study III, ALK immunohistochemistry was positive in 22 of 24 MCC tumors 
(91,7%) with antibody clone D5F3 and in 4 of 26 tumors (15.4%) with clone 
5A4. Staining was clearly more intense with antibody D5F3, and it detected 
ALK positivity more frequently than the clone 5A4 (Figure 9).  
 
 
 
21 84 female Right 
shoulder 
none pos  yes  +  +   - none 
22 82 male Neck none neg  yes na na na none 
23 85 male Left arm Axillary 
lymph nodes 
pos  yes  +  -  - EGFR, TP53 
24 84 female Back none neg  yes  -  -  - none 
25 87 female cheek none pos  yes na na na TP53 
26 60 female Left foot Heart, lung neg  yes  +  +   - none 
27 80 male Right breast none neg no  + (+)  - PIK3CA 
28 83 female Front of left 
ear 
none neg no  + (+)  - PIK3CA 
29 69 female Flank none pos no  +  +   +  KIT, MPL, 
PIK3CA, 
TP53 
30 68 female Upper 
abdomen 
none neg no  +  +   - APC, 
CTNNB1, 
MET, 
PIK3CA, 
STK11, 
TP53, VHL 
31 79 female Right 
buttock 
none pos no  +  -  - none 
32 100 female Right cheek none neg no  +  +   +  SMO 
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Figure 9. The figure illustrates the difference between ALK positive staining when using 
antibody clone 54A (Left) and clone D5F3 (Right) (III). 
 
 
In study IV, 110 tumor samples in TMA slides were stained for ALK with 
antibody clone D5F3. During microscopic assessment of the stainings, we 
noticed that individual samples stained with different intensity. Therefore, 
we interpreted the expression as either strong positive, weak positive or 
negative. (Figure 10) Consequently, there were 56 strong positive, 16 weak 
positive and 38 negative tumors (51%, 15% and 34% respectively). In further 
analysis, ALK expression did not correlate with patient sex, tumor location or 
development of metastasis or MCC-specific death. However, we recorded 
that ALK expression associated with MCV positivity. 78% of the MCV-positive 
tumors were ALK positive, while only 32% of the MCC-negative tumors 
expressed ALK. This association was pronounced with tumors that expressed 
strong positivity for ALK, since 51 of the 56 (91%) strong positive tumors 
were MCV positive (Figure 12). This association of ALK positivity to MCV 
positivity was statistically significant (p < 0.05).  
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Figure 10. Strong ALK staining on the left and weak staining on the right(IV).  
 
 
 
5.4.2 EGFR immunohistochemistry 
 
In study II, EGFR IHC staining was negative in all 27 MCC cases studied. In 
study IV, we recorded an unprecedented expression of EGFR in 7 of the 111 
MCC tumors. There was absolute association between EGFR positivity and 
MCV negativity since, all of those 7 tumors were MCV-negative. (Figure 11) 
EGFR expression did not correlate to patient sex, tumor location, 
development of metastasis or MCC specific death (IV). From those seven 
EGFR positive tumors, three (42,9%) developed metastasis, while from 104 
EGFR negative tumors only 25 (24,0%) developed metastasis, proposing that 
disease course of EGFR positive MCC might be more aggressive than in EGFR 
negative disease. However, no statistical significance was observed 
regarding this matter.  
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Figure 11. The fractions of EGFR positive and negative cases according to MCV-status (IV). 
 
 
5.4.3 EZH2 immunohistochemistry 
 
In study IV, we observed frequent expression of EZH2 by 
immunohistochemistry. Similarly to ALK stainings, we interpreted the 
staining as either strong positive, weak positive or negative. From 111 
tumors, 84 (76 %) showed strong positivity, while 18 (16%) were weak 
positive, and only 9 (8%) were negative. EZH2 expression was not associated 
with MCV-status of the tumors, development of metastasis or MCC-specific 
survival (Figure 12). 
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Figure 12. Number of MCV-positive and MCV-negative cases according to ALK and EZH2 
staining (IV). 
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6 DISCUSSION 
 
6.1 Patients 
 
Our cohort of 32 MCC patients involved in studies I, II and III was selected 
based on the known MCV status of the tumor and sufficient amount of 
sample available. This cohort was selected mainly so that there would be 
equal numbers of MCV-positive and negative cases, and therefore it does 
not reflect a random cohort of 32 MCC patients.  
 
The group of 112 MCC patients in study IV reflects quite well an average MCC 
cohort, since previous literature shows that tumors are frequently located 
on the head and neck (over 50%), the mean age of the patients is around 75 
years and around 80% tumor MCC positivity is observed (Agelli 2010, Kukko 
2012, Kukko 2012, Albores-Saavedra 2010, Sihto 2009). In this cohort, a clear 
female predominance was seen, however previous literature is ambivalent 
regarding the typical male-to-female ratio in MCC (Kukko 2012, Hodgson 
2005, Allen 2005, Lyhne 2011). In our cohort of 112 patients, the 
development of metastasis was more frequent (25% vs 7-12%) than what 
was anticipated (Lebbe 2015, Harms 2016, Lemos 2010). However, the 
mortality in our cohort was lower than what was estimated in the literature 
(Lemos 2010, Becker 2010). Lower mortality in our cohort might be due to 
short follow-up in more recent cases that were diagnosed in the early 2010s 
(Follow-up ended 2013). Large variation in follow-up time between the cases 
is also a major limitation of this study and may impair the association of 
molecular alterations and survival. However, due to low incidence and high 
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mortality of MCC, performing equalized follow-up, for example 5 years, for 
all patients in the cohort is challenging.  
  
 
6.2 MicroRNA profiles (Study I) 
 
In study I we compared the miRNA expression of MCC tumors according to 
tumor MCV status. We recorded differential expression of four miRNAs in 
MCV-negative and MCV-positive tumors with both Microarray and qPCR 
analysis. We did not find correlation between miRNA expression and disease 
stage or survival, and larger studies are required to ascertain whether 
miRNAs have prognostic value in MCC. 
The most intriguing finding in the miRNA study was the underexpression of 
miR-34a in MCV-negative tumors. In concordance to our results, another 
group had reported miR-34a underexpression in MCV-negative MCC 
compared to MCV-positive (Xie 2014). miR-34a is considered a tumor 
suppressor miRNA that acts alongside tumor suppressor protein p53, 
activating it and increasing its own production via p53 (He 2007, Yamakuchi 
2009, Yamakuchi 2008). Thus, underexpression of miR-34a could promote 
oncogenesis in MCV-negative MCC. In comparison to our study, Xie et al. also 
found underexpression of miR-30a in MCV-negative tumors. In addition, 
they reported overexpression of miR-375, miR-769-5p and underexpression 
of miR-203 in MCV-positive tumors. Those three miRNAs showed no 
differential expression in our study. It could be that some miRNAs, like miR-
34a are typically dysregulated in MCC, but there is also divergence in the 
miRNA profiles between tumors. 
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To the best of our knowledge, only these two studies assessing miRNA 
profiles of MCV-positive and MCV-negative MCCs have been conducted, and 
it is thus intriguing to gain more knowledge about miRNAs, their relation to 
MCV and whether they have use as biomarkers or have other clinical value 
in MCC cases. Our findings, that are partly in concordance with another 
study, suggest that miRNA profiles in MCC tumors do differ according to MCV 
status. However, whether they have a role in pathogenesis or clinical use as 
biomarkers in MCC remains to be deciphered.  
 
 
6.3 Gene mutations (Study II) 
 
In study II we used targeted NGS for seeking mutations of known cancer 
genes in MCC tumors. Generally, mutations were more frequent in MCV-
negative tumors, and even though we were unable to demonstrate that it is 
statistically significant, (p-value 0.24) our observation sits well with other 
mutational studies that were published consecutively in 2015-2016. All of 
these studies report more numerous mutations in MCV-negative MCC 
(Wong 2015, Goh 2016, Harms 2015). Notably, mutations in MCV-negative 
tumors at nucleotide level are commonly Cytosine to Thymine transitions, 
which is considered as signature nucleotide change caused by UV radiation. 
This provides further evidence that especially for MCV-negative tumors, the 
UV is an undisputed etiological factor (Wong 2015, Harms 2015, Alexandrov 
2013). 
TP53 mutations are previously reported to associate with MCV-negative 
tumors (Erstad 2014, Sihto 2011). On the contrary, we recorded them also 
in MCV-positive tumors. The most notable finding was EGFR mutations in 6 
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tumors (22% of 27) which had not been published before in MCC. 
Unfortunately these mutations were not cofirmed by Sanger sequencing (III), 
however that could be due to low mutant allele frequency of the tumors. 
Non-cancerous tissue obtained from 2 of these 6 MCC patients was negative 
for EGFR mutations, suggesting that the mutations in the tumors were real 
and somatic. Unfortunately, we failed to witness that these mutations lead 
to activation of the EGFR gene and EGFR protein expression. A future interest 
would be to go back to these samples and examine whether the EGFR 
receptor is active in these tumors that contained EGFR mutations. Hotspot 
mutations of EGFR are reported in various malignancies, including NSCLC 
(Murray 2006), where some of the mutations predict responsiveness to 
EGFR tyrosine kinase inhibitors (Brandao 2012, Han 2005). In fact, at least 
one of the mutations that we recorded in MCC is reported responsive to 
EGFR inhibitor in lung adenocarcinoma (Brandao 2012). Since there are 
hotspot mutations of EGFR also in MCC, it could be a potential therapeutic 
target in the subset of MCC tumors, provided that the mutations are 
activating.  
In keeping with previous a exome sequencing study, we recorded RB1 
mutations only in MCV-negative tumors (Cimino 2014). In our study, novel 
mutations were seen in three MCV-negative tumors. These mutations were 
not recorded in either the dbSNP142 or the COSMIC database. 
(http://cancer.sanger.ac.uk/cosmic) We also found PIK3CA and KIT 
mutations more commonly in MCV-negative tumors. PIK3CA mutations in 
MCV-negative tumors are also reported by another research group (Nardi 
2012). They suggested that PIK3 signaling might have a pathologic role in the 
subset of MCC. 
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In conclusion, many mutational studies have been conducted for MCC, and 
no prevalent driver mutations have been found. It seems that some genes 
might be contributing to the pathogenesis of a subset of MCC tumors, and 
especially MCV-negative tumors are associated with more potential 
oncogenic genes.  Thus, new molecular targets for treatment might emerge.  
 
6.4 RNA expression (Study III) 
 
In study III, we utilized targeted NGS to explore the expression of cancer 
genes at RNA level in MCC tumors. To our knowledge, this was the first study 
to address the RNA expression of oncogenes and tumor suppressors in MCC. 
The expression in the tumors was compared to normal skin and in addition, 
the MCV-negative and MCV-positive tumors were compared. The most 
notable overexpressed genes were ALK and EZH2, while EGFR emerged as 
strongly underexpressed. Six genes  - MET, NOTCH1, FGFR3, SMO, JAK3 and 
NPM1 - were differently expressed in MCV-positive and MCV-negative 
tumors, adding more to the landscape of varying molecular characteristics 
of the two MCC subgroups. 
We recorded over 7-fold overexpression of ALK in our cohort of 26 MCC 
tumors. Particularly high expression of ALK mRNA was present in 22/26 
tumors regardless of tumor MCV status. ALK is known for its involvement in 
fusion proteins such as NPM-ALK in ALCL (Morris 1994). To investigate 
potential ALK fusion in MCC, we performed Fluorescence in situ 
hybridization (FISH) for the tumor samples, but no fusion was recorded. 
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However, in five tumors there were indications of possible gain or polyploidy 
involving ALK. Since no chromosomal rearrangements or activating ALK 
mutations are present, the mechanism of ALK mRNA expression in MCC 
remains unknown.  
We also observed underexpression of EGFR mRNA in MCC tumors compared 
to normal skin in study III. Although the underexpression was almost 5-fold, 
this observation might be due to strong expression of EGFR in normal skin 
and not because of nonexistent expression in MCC tumors. 
EZH2 mRNA expression in MCC was first reported by our group (III). We 
detected high expression of EZH2 regardless of tumor MCV status. One study 
has reported activating EZH2 mutation in one MCC case (Harms 2016), but 
these mutations have been absent in other mutational studies in addition to 
our study II (Goh 2016, Harms 2015). Thus, the overexpression of EZH2 in 
MCC might be due to epigenetic regulation rather than genetic origin. 
Whether EZH2 functions as a silencer of tumor suppressors in MCC is 
undeciphered.  
 
6.5 Protein expression (Studies II, III and IV) 
 
Studies II and III were essentially sequencing projects, but based on the 
sequencing results, we also analyzed protein expression by 
immunohistochemistry with the same tumor samples that were sequenced. 
In study IV, we wanted to further explore the protein expression of the three 
standout oncoproteins in previous studies, ALK, EGFR and EZH2. Therefore, 
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we utilized TMAs containing 112 MCC samples to study expression of these 
proteins on a  larger scale (IV). 
In study III, we used two antibodies (D5F3 and 5A4) for detecting ALK 
expression and saw that D5F3 detected ALK more frequently. Therefore, in 
study IV we only used antibody clone D5F3 for ALK staining. ALK expression 
by IHC in MCC has been previously studied. They reported frequency of ALK 
positivity as high as 93.8% on 32 MCC tumors studied (Filtenborg-Barnkob 
2013). In study III, we recorded expression frequency almost as high as they 
did with antibody D5F3. However, when we investigated the expression in a 
much larger tumor cohort in study IV, we showed that ALK expression is 
common in MCC but not as common as previously reported. A notable, novel 
finding was the correlation of ALK positivity to MCV positivity which has not 
been published before. In study III, we recorded ALK mRNA expression 
regardless of MCV status. It remains to be discovered why ALK expression at 
protein level associates with MCV positivity while ALK mRNA seems to be 
expressed in all MCC tumors. A future interest would be to study the possible 
interaction of MCV and ALK; whether MCV infection facilitates ALK 
expression in MCC.   
Brunner et al. had previously studied EGFR expression by 
immunohistochemistry in 32 MCC TMA samples, and the staining was 
negative in all cases (Brunner 2008). Yet, since we recorded EGFR mutations 
in a subset of MCC tumors (II), we were hopeful to discover EGFR protein 
expression in MCC. However, in study II, EGFR staining was negative in all 27 
MCC cases studied. In that study, we used an antibody clone that reacts with 
the extracellular domain of EGFR. We hypothesized that the reason we could 
not detect EGFR protein expression in any of the tumor samples was either 
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because we used an antibody that does not detect truncated forms of the 
EGFR or because only a few tumor cells contain the EGFR mutation.  In study 
IV, we used a different type of antibody clone that binds to the intracellular 
domain of EGFR and detects constitutively active and truncated forms of 
EGFR (Mascaux 2011). This antibody clone (5B7) has been used in NSCLC 
samples, and positive staining was found to predict the efficacy of EGFR 
Tyrosine Kinase inhibitor treatment (Mascaux 2011, Chang 2016). With this 
antibody, we recorded EGFR expression in 23% ( 7/31) of the MCV-negative 
tumors, while none of the MCV-positive tumors expressed EGFR (IV). Hence, 
we propose that EGFR might be a desirable treatment target also in the 
subset of MCC that express EGFR by immunohistochemistry.  
 
In study IV, we observed frequent expression of EZH2 in MCC tumors 
regardless of MCV-status. Harms et al. had studied EZH2 expression in 29 
primary MCCs, and they reported that strong expression of EZH2 associates 
with disease progression (Harms 2017). They did not observe completely 
negative cases, while our much larger cohort of primary MCCs harbored 8% 
of negative tumors. They also showed that EZH2 expression is higher on 
metastases compared to primary tumors. In contradiction to their study, we 
only had primary tumors in our cohort, and we did not find correlation 
between primary tumor EZH2 expression and development of metastasis or 
MCC-specific death. Therefore, a suggestion can be made that EZH2 is not a 
prognostic factor but rather could be a potential therapeutic target since the 
majority of MCC tumors express EZH2.  
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7 CONCLUSIONS 
 
In study I, we showed that MicroRNA profiles of MCV-positive and MCV-
negative tumors are partially distinct. However, their potential in clinical use 
is uncharted. Notably MiRNA-34a is underexpressed in MCV-negative 
tumors and its deprivation might promote pathogenesis of MCV-negative 
MCC.  
 
Mutational analysis (Study II) of MCC recorded that MCV-negative tumors 
harbor gene mutations more frequently compared to MCV-positive, 
however no frequently presenting driver mutations were observed. 
However, a subset of MCC tumors contain EGFR mutations unprecedented 
in MCC. Further, in our immunohistochemistry study (study IV), we observed 
expression of EGFR in small proportion of MCV-negative tumors, suggesting 
that these tumors might respond to EGFR inhibitors.  
 
RNA sequencing (Study III) introduced that ALK is commonly expressed at 
RNA level in MCC tumors regardless of tumor MCV status, although ALK 
fusions are absent. Intriguingly we recorded that expression of ALK at 
protein level by immunohistochemistry associates strongly with tumor MCV 
positivity (Study IV). However, the mechanism of ALK overexpression in MCC 
remains unknown.  
 
Based on RNA sequencing in study III and immunohistochemistry in study IV, 
we concluded that EZH2 is frequently expressed in MCC both at RNA and 
protein level regardless of MCV status and might be a potential therapeutic 
target.  
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In statistical analysis comparing protein expression and clinical parameters 
of MCC patients; (Study IV) Expression of ALK, EGFR and EZH2 does not 
appear to correlate with development of metastasis or MCC-specific 
mortality. 
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